Calendar of Events
Tuesday, July 4
Stay updated with breaking news from Bleeding Disorders. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Once-weekly prophylaxis with a high-sustained factor VIII replacement therapy exhibited effective bleed protection for children with severe hemophilia A, according to the agent’s manufacturer.Antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein (Altuviiio, Sanofi) is approved in the United States for routine prophylaxis and on-demand treatment to control bleeding episodes for
ALTUVIIIOTM late-breaking data at ISTH demonstrates highly effective bleed protection in children with severe hemophilia A with once-weekly dosing ...
ALTUVIIIOTM late-breaking data at ISTH demonstrates highly effective bleed protection in children with severe hemophilia A with once-weekly dosing XTEND-Kids data confirm the efficacy and safety profile of ALTUVIIIO with simple, weekly 50...